THE TGA has approved Yeytuo (lenacapavir, Gilead Sciences) for pre-exposure prophylaxis (PreP) for HIV.
The twice-yearly treatment is used to reduce the risk of HIV-1 in adults and adolescents 16 years of age and older who weigh at least 35kg.
Lencapavir is also available as Sunleca, used to treat HIV in combination with other antiretrovirals.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 26
